Rachid C. Baz

Hematology | Oncology
12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 108 publications

Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial.

Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial.

Journal: BMJ (Clinical research ed.)
Published: July 23, 2026

Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma.

Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma.

Journal: Cancer research
Published: March 10, 2026

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 11, 2026

High CTC, high-risk cytogenetics: a dangerous duo in MM?

High CTC, high-risk cytogenetics: a dangerous duo in MM?

Journal: Blood
Published: January 22, 2026

Epigenome-Wide Association Studies of Proteasome Inhibitor-Related Cardiotoxicity in Patients with Multiple Myeloma.

Epigenome-Wide Association Studies of Proteasome Inhibitor-Related Cardiotoxicity in Patients with Multiple Myeloma.

Journal: Cancers
Published: January 03, 2026

Atorvastatin Protects Against Deleterious Carfilzomib-Induced Transcriptional Changes in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Atorvastatin Protects Against Deleterious Carfilzomib-Induced Transcriptional Changes in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Journal: International journal of molecular sciences
Published: December 22, 2025

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Journal: bioRxiv : the preprint server for biology
Published: December 19, 2025

Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1.

Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1.

Journal: Blood neoplasia
Published: December 09, 2025

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Journal: Bone marrow transplantation
Published: November 07, 2025

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Journal: Blood cancer journal
Published: November 04, 2025

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.

Journal: Blood advances
Published: October 30, 2025

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.

Journal: Blood advances
Published: October 30, 2025
Showing 1-12 of 108

Last Updated: 09/26/2026